Copy to clipboard 
Vericel reported 1Q25 orthopedic sales of $46.3 million, up 15.2% compared to the first quarter of 2024.
Despite the seasonally slower first quarter, the strong underlying fundamentals of MACI drove double-digit biopsy growth and the second-highest number of biopsies in any quarter since launch.
MACI Arthro’s early launch is off to a strong start. Vericel trained 400 surgeons through April, eclipsing the pace set by MACI during its 2017 launch. MACI Arthro also seems to be expanding the company’s target addressable market beyond its intended use.
“MACI Arthro is being used in a meaningful number of cases for patients with trochlea defects, an area of the knee behind the kneecap where MACI historically had low single digit penetration,” said Vericel CEO Nick Colangelo. “The trochlea defect segment of MACI’s addressable market is similar in size to the patella segment at approximately 10,000 patients per year and has the potential to be a significant source of business and a meaningful driver of upside MACI growth beyond the treatment of femoral condyle defects.”
Based on the strong launch and underlying demand for MACI, Vericel plans to expand its sales force in the second half of the year.
The company expects total sales growth between 20% and 23% for 2025.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Sports Medicine | $46.3 | $40.2 | $6.1 | 15.2% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $52.6 | |
| Cost of Sales | $16.3 | 31% |
| General and Admin | $41.8 | 79.5% |
| R & D | $7.3 | 13.8% |
| Other | ($1.5) | (2.9%) |
| Net Earnings | ($11.2) | (21.4%) |
Vericel reported 1Q25 orthopedic sales of $46.3 million, up 15.2% compared to the first quarter of 2024.
Despite the seasonally slower first quarter, the strong underlying fundamentals of MACI drove double-digit biopsy growth and the second-highest number of biopsies in any quarter since launch.
MACI Arthro's early launch is off to a...
Vericel reported 1Q25 orthopedic sales of $46.3 million, up 15.2% compared to the first quarter of 2024.
Despite the seasonally slower first quarter, the strong underlying fundamentals of MACI drove double-digit biopsy growth and the second-highest number of biopsies in any quarter since launch.
MACI Arthro’s early launch is off to a strong start. Vericel trained 400 surgeons through April, eclipsing the pace set by MACI during its 2017 launch. MACI Arthro also seems to be expanding the company’s target addressable market beyond its intended use.
“MACI Arthro is being used in a meaningful number of cases for patients with trochlea defects, an area of the knee behind the kneecap where MACI historically had low single digit penetration,” said Vericel CEO Nick Colangelo. “The trochlea defect segment of MACI’s addressable market is similar in size to the patella segment at approximately 10,000 patients per year and has the potential to be a significant source of business and a meaningful driver of upside MACI growth beyond the treatment of femoral condyle defects.”
Based on the strong launch and underlying demand for MACI, Vericel plans to expand its sales force in the second half of the year.
The company expects total sales growth between 20% and 23% for 2025.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Sports Medicine | $46.3 | $40.2 | $6.1 | 15.2% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $52.6 | |
| Cost of Sales | $16.3 | 31% |
| General and Admin | $41.8 | 79.5% |
| R & D | $7.3 | 13.8% |
| Other | ($1.5) | (2.9%) |
| Net Earnings | ($11.2) | (21.4%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
